Skip to content
Clinical Trials – home

Ziekenhuisgroep Twente Stichting

Research site

The Netherlands Zilvermeeuw 1, 7609 PP Almelo, The Netherlands

  • 26 trials recruiting
  • Chronic kidney disease · Hormone-refractory prostate cancer · Arteriosclerosis
  • Adults and children

About Specializations

Ziekenhuisgroep Twente Stichting in Almelo, The Netherlands specialises in clinical trials of conditions such as Chronic kidney disease, Hormone-refractory prostate cancer, Arteriosclerosis, Hormone receptor positive HER2 negative breast cancer, and other specialisations. This site conducts important research.

Main research areas of the site

Oncology and Cancer Care

At Ziekenhuisgroep Twente Stichting in Almelo, a major share of research focuses on neoplasms and advanced cancer care, especially breast cancer, prostate cancer, non-small cell lung cancer, colorectal cancer, and gastroesophageal cancers. These studies are designed to improve treatment effectiveness, refine care strategies, and test new combinations or sequencing of cancer therapies.

  • Evaluating new treatment approaches for metastatic and locally advanced cancers
  • Improving outcomes in HER2-positive, hormone receptor-positive, and triple negative breast cancer
  • Testing targeted therapies and immunotherapy-based strategies in solid tumors and blood cancers
  • Studying ways to optimize survival, disease control, and tolerability in oncology care

The site’s Internal Oncology department contributes to a broad portfolio of cancer trials, including research on tumor-specific diagnostics and treatment personalization.

Hematology and Blood Disorders

Clinical research also covers hemic and lymphatic diseases, with studies in diffuse large B-cell lymphoma, multiple myeloma, non-Hodgkin lymphoma, and T-cell prolymphocytic leukemia. The main goal is to improve treatment benefit while reducing toxicity and long-term complications.

  • Assessing better treatment strategies for lymphoma and myeloma
  • Studying prevention of treatment-related heart damage in blood cancer care
  • Exploring personalized targeted therapy for hematologic malignancies
  • Measuring how therapy choices affect disease control and safety

This research reflects a strong interest in balancing effectiveness with quality of life for patients with complex blood cancers.

Cardiovascular, Kidney, and Metabolic Research

Another important research area includes cardiovascular diseases, chronic kidney disease, and nutritional and metabolic diseases, with studies in atherosclerotic cardiovascular disease, heart failure prevention, albuminuria, type 2 diabetes, and obesity. These trials aim to reduce major health events and improve long-term organ protection.

  • Testing therapies to lower cardiovascular risk in high-risk patients
  • Studying treatments that reduce kidney damage and albuminuria
  • Evaluating approaches for patients with diabetes, obesity, and related complications
  • Looking at ways to prevent heart failure and kidney failure

The research portfolio shows a clear focus on chronic disease management and prevention across interconnected heart, kidney, and metabolic conditions.

Digestive, Respiratory, and Surgical Conditions

The site also investigates digestive system diseases, respiratory tract diseases, and selected pathological conditions, including gastric cancer, appendicitis, post-surgical neuropathic pain, acute respiratory tract infection, and pneumonia. These studies often focus on improving recovery, staging, and treatment outcomes in hospital-based care.

  • Evaluating surgical and supportive approaches to reduce complications
  • Improving diagnosis and staging in advanced gastric cancer
  • Testing strategies to support recovery in respiratory infections and pneumonia
  • Assessing pain relief and complication prevention after surgery

Research in these fields combines practical hospital care questions with efforts to improve patient comfort, safety, and clinical decision-making.

Diagnostic and Personalized Medicine

Several trials at Ziekenhuisgroep Twente Stichting explore diagnostic and therapeutic techniques, including imaging-based selection tools, biomarker-guided treatment, and personalized therapy matching. The diseases studied range from prostate cancer and gastric cancer to breast cancer and advanced solid tumors.

  • Using imaging and biomarker tools to improve treatment selection
  • Personalizing cancer therapy based on tumor characteristics
  • Studying whether diagnostic advances can reduce unnecessary procedures
  • Supporting more tailored and efficient care pathways

This work highlights a strong interest in precision medicine, with research aimed at making treatment choices more effective and better matched to each patient.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location
Zilvermeeuw 17609 PP AlmeloThe Netherlands
Recruiting now
26 trials
Conditions studied
66

More sites in AlmeloThe Netherlands

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Condition
Type of trial
Recruitment status
Quick filters

59 clinical trials

Obesity+2

Recruiting

Effect of zenagamtide on major adverse cardiovascular events in overweight or obese adults with established atherosclerotic cardiovascular disease

Investigational
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years
  • Substances:POLYPEPTIDE CONSISTING OF A GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONIST AND AN AMYLIN RECEPTOR AGONIST, CONNECTED BY A LINKER WITH 4 GLYCINE RESIDUES, AND CONNECTED TO A C18 FATTY ACID SIDE CHAIN
  • Sponsor:Novo Nordisk A/S
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Baxdrostat
  • Sponsor:AstraZeneca AB

Phase III trial evaluating ianalumab with background drug combination in patients with Sjögren's disease

Registered drug
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Emtricitabine
  • Sponsor:Novartis Pharma AG

Phase 3 Study of Etripamil Nasal Spray Compared with Placebo in Patients with Atrial Fibrillation and Rapid Ventricular Rate

Investigational
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Etripamil
  • Sponsor:Milestone Pharmaceuticals Inc.

Efficacy and safety of sarilumab plus prednisone versus prednisone alone in adults with early polymyalgia rheumatica

Registered drug
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Prednisone
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Study of MK-1084 plus durvalumab versus placebo plus durvalumab in patients with locally advanced KRAS G12C‑mutant non‑small cell lung cancer after chemoradiotherapy

Registered drug
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab
  • Sponsor:Merck Sharp & Dohme LLC

Study of pembrolizumab, capecitabine, or olaparib in patients with early-stage triple negative breast cancer and remaining disease after initial treatment

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting

Study of drug combination therapy for patients with lymph node-positive esophageal and esophagogastric junction cancer using carboplatin, paclitaxel, fluorouracil, folinic acid, docetaxel and oxaliplatin

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)

Study Comparing Ifinatamab Deruxtecan and Docetaxel for Patients with Advanced Prostate Cancer Resistant to Hormone Therapy

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Codeine Phosphate
  • Sponsor:Merck Sharp & Dohme LLC

Gastric cancer

Recruiting

Study on [18F]-AlF-FAPI-74 for Staging Advanced Stomach Cancer in Patients Using PET/CT and Laparoscopy

InvestigationalNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years
  • Substances:[Al[18F]F]Fapi-74
  • Sponsor:Leids Universitair Medisch Centrum (LUMC)

Study on High-Dose Short-Course Antibiotics for Critically Ill Patients with Pneumonia, Intra-Abdominal, or Bloodstream Infections: Ceftriaxone, Linezolid, and Cefotaxime

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Cefotaxime
  • Sponsor:Universitair Ziekenhuis Gent

Appendicitis+4

Recruiting

Study on Using Gentamicin and Clindamycin to Prevent Abscesses After Surgery for Complicated Appendicitis in Patients

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Clindamycin
  • Sponsor:Amsterdam UMC Stichting
Is this your site?

Join our network of research sites

Get verified: confirm your contact details and recruitment status with us, appear first on the pages of your trials and receive patient requests directly.

See the offer for sites
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.